Amneal Pharmaceuticals announced Friday that its ANDA-approved product is now available on the U.S. market, marking a new competitive entry for the corresponding branded therapy. This regulatory green light ensures continued access for patients while positioning Amneal to capture revenue in a sector increasingly driven by generic penetration.